Newron and EA Pharma secure landmark licensing deal to advance schizophrenia treatment
In a move set to transform treatment options for patients with schizophrenia, Newron Pharmaceuticals S.p.A. ("Newron") has entered into a high-value licensing agreement with EA ... Read More
Seaport Therapeutics rakes in $100m for neuropsychiatric medicine advancement
Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical company, has successfully closed an oversubscribed Series A financing round, securing $100 million. This significant milestone was led by ... Read More